MTHFR & Methylation: What it actually means for your health

What Methylation Actually Does

Methylation is a biochemical process that happens billions of times per second in every cell of your body. It involves transferring a methyl group (one carbon atom and three hydrogen atoms) from one molecule to another. That sounds abstract, but the processes it controls are fundamental to health.

Methylation is how your body repairs DNA, which protects against cancer and premature ageing. It is how you produce and recycle neurotransmitters like serotonin, dopamine, and noradrenaline, which govern mood, motivation, focus, and sleep. It is how you detoxify, converting harmful substances into forms the body can eliminate. It is how you regulate gene expression, turning genes on and off in response to your environment (this is the field of epigenetics). It is how you produce glutathione, the body’s master antioxidant and primary detox molecule. And it is how you metabolise oestrogen, homocysteine, and histamine.

When methylation is running well, you do not notice it. When it slows down, you notice everything. Fatigue, brain fog, anxiety, poor stress tolerance, hormonal imbalance, recurrent miscarriage, chemical sensitivity, and slow recovery from illness are all common presentations of methylation under strain.

Think of methylation as your body’s background operating system. It does not perform any single dramatic function. It makes everything else run. When it slows, nothing works as well as it should, and the symptoms that appear can look like a dozen different conditions depending on which downstream system is affected most.

What MTHFR Variants Mean (and What They Do Not Mean)

The MTHFR gene provides instructions for producing an enzyme called methylenetetrahydrofolate reductase. This enzyme converts dietary folate into its active form, methylfolate, which the body needs for the methylation cycle to run.

If you carry a variant (sometimes called a polymorphism or mutation), the enzyme works at reduced efficiency. The C677T variant reduces enzyme activity by roughly thirty per cent in heterozygous form (one copy) and up to seventy per cent in homozygous form (two copies). The A1298C variant has a milder effect on its own but compounds the problem when combined with C677T.

What this does not mean is that your methylation is broken. It means the enzyme works more slowly. In good conditions, with adequate nutrient intake, healthy gut absorption, low stress, and minimal toxic load, most people with MTHFR variants function without problems. The gene has been in the human population for thousands of years. It is not a disease.

What it does mean is that your margin for error is smaller. When demand for methylation increases, through pregnancy, chronic illness, toxic exposure, prolonged stress, or nutrient depletion, the reduced enzyme efficiency becomes a bottleneck. The system cannot keep up with demand. Homocysteine accumulates because it is not being recycled efficiently. Neurotransmitter production slows. Detoxification falters. DNA repair becomes less reliable. Glutathione levels drop.

This is what I mean by “the gene under load.” The variant was always there. The load is what made it matter.

I see this pattern every week in my practice. A patient who was fine for years, functional, healthy, productive. Then something happened. A pregnancy. A period of sustained stress. A mould exposure. A viral infection. And suddenly the system could not cope. The gene had not changed. The demand on the gene had exceeded its reduced capacity.

Beyond MTHFR: The Methylation Network

MTHFR gets the most attention, but it is one gene in a network of enzymes that work together. Focusing on MTHFR alone is like diagnosing a car problem by looking only at the spark plugs. In clinical practice, I look at the whole methylation pathway.

MTR (methionine synthase)

recycles homocysteine back into methionine, the amino acid that starts the methylation cycle. It requires active B12 as a cofactor. If B12 is low, this step stalls regardless of MTHFR status. This is one of the most common bottlenecks I find: a patient supplementing methylfolate for their MTHFR variant but not addressing the B12 deficiency that is blocking the next step in the cycle.

MTRR (methionine synthase reductase)

regenerates the active form of B12 that MTR needs. Variants in MTRR can impair B12 utilisation even when blood levels appear adequate. This is why active B12 testing matters more than serum B12.

CBS (cystathionine beta-synthase)

directs homocysteine into the transsulfuration pathway, which produces glutathione and taurine. Variants in CBS can alter the flow between methylation and detoxification. This becomes clinically relevant when a patient needs both methylation support and detox support simultaneously.

COMT (catechol-O-methyltransferase)

is responsible for breaking down catecholamines like dopamine, adrenaline, and noradrenaline, as well as oestrogen metabolites. Slow COMT variants are associated with anxiety, oestrogen dominance, sensitivity to stress, and difficulty clearing stimulatory neurotransmitters. Fast COMT variants are associated with lower mood, lower pain tolerance, and a need for more stimulation. COMT status directly influences how a patient responds to methyl donors. Give methylfolate and methyl B12 to a slow COMT patient and their anxiety can spike dramatically because the methyl donors increase neurotransmitter production that their slow COMT cannot clear fast enough.

The clinical picture emerges from the combination of these variants, not from any single one. A patient with MTHFR C677T, MTRR, and slow COMT under high stress and with poor gut absorption is in a very different position from someone with MTHFR C677T alone who eats well and sleeps eight hours a night. The genetics set the terrain. The environment determines whether it becomes a problem.

What Standard Testing Misses

If your GP has tested your B12 and folate and told you they are “normal,” that may not be the full picture. In fact, it is one of the most commonly misleading results I encounter.

Standard B12 testing measures serum B12, which includes both active and inactive forms. Your serum B12 can be within range while your active B12 (holotranscobalamin, the form your cells actually use) is severely depleted. I see this regularly. A patient with a serum B12 of 280 pmol/L looks normal on the lab report. Their active B12 is 42 pmol/L, well below the optimal of above 80. Their methylmalonic acid on the organic acids test is elevated, confirming functional B12 deficiency at the cellular level. The standard test said fine. The functional tests said the opposite.

This is not a rare finding. It is one of the most common discrepancies I see. And it has significant clinical consequences. A patient being told their B12 is fine when their cells are starving for it will continue to suffer from fatigue, brain fog, mood issues, and poor methylation while being reassured that nothing is wrong.

Homocysteine

is the single most useful blood marker for methylation function. Homocysteine is an amino acid that is recycled by the methylation cycle. When the cycle is running efficiently, homocysteine stays low. When the cycle is impaired, homocysteine accumulates. I want to see homocysteine below 7 µmol/L. Levels above 10 indicate that the methylation cycle is not processing efficiently. Yet most GPs do not include homocysteine on a standard blood panel, and when they do, they use a lab range of up to 15, which misses clinically significant elevation. A homocysteine of 12 is “normal” by lab standards but is associated with increased cardiovascular risk, impaired detoxification, and reduced neurotransmitter production.

The organic acids test

adds critical functional detail. Methylmalonic acid confirms whether B12 is functioning at the cellular level, regardless of what the blood level shows. FIGLU (formiminoglutamic acid) confirms whether folate is being utilised effectively. Pyroglutamic acid indicates glutathione depletion, meaning the detox arm of the methylation pathway is failing. Quinolinate elevation suggests functional B6 deficiency, which affects neurotransmitter production.

Genetic testing

identifies the variants but does not tell you how they are expressing right now. You need the biochemistry (homocysteine, active B12, folate, organic acids) alongside the genetics to see the full picture. The genes tell you where the vulnerabilities are. The blood and urine tests tell you whether those vulnerabilities are currently causing problems. I have seen patients with significant MTHFR variants and perfect methylation biochemistry because their lifestyle and nutrient status were supporting the system adequately. And I have seen patients with minor variants and severe methylation dysfunction because their gut was not absorbing the nutrients the cycle needed.

When Methylation Matters Clinically

In my practice, methylation becomes clinically significant in the following situations.

Recurrent pregnancy loss.

This is one of the most heartbreaking presentations I see, and one of the most rewarding to treat. Elevated homocysteine and poor methylation capacity impair implantation, placental development, and early embryonic growth. Folate is required for neural tube closure and DNA replication in the rapidly dividing embryo. When methylation is impaired, the pregnancy fails at the point of highest demand, usually between weeks six and eight.

I have treated patients with three or more miscarriages who had been told it was “bad luck” or “chromosomal abnormality.” When we tested their methylation pathway, the picture was clear: MTHFR variants combined with depleted B12, low folate, elevated homocysteine, and gut malabsorption. Once the methylation pathway was supported with the right active nutrients, the gut was repaired, and homocysteine normalised, they conceived and carried to term. I have seen this pattern resolve repeatedly. It is not luck. It is biology.

Treatment-resistant mental health symptoms.

Undermethylation is associated with depression that does not respond to standard SSRI medication, OCD tendencies, perfectionism, high inner drive combined with low mood, seasonal mood patterns, and a tendency toward ritual and routine. These patients often have elevated homocysteine and respond to methylation support: SAMe, methionine, methylfolate, and methyl B12.

Overmethylation is associated with anxiety, sensory sensitivity, adverse reactions to methyl donors (feeling worse on methylfolate or methyl B12), food and chemical sensitivities, and a tendency toward paranoia under stress. These patients respond to folate, niacin, and calming support rather than methyl donors. Giving methyl donors to an overmethylator makes them dramatically worse. This is why blanket “take methylfolate for MTHFR” advice is dangerous without proper testing.

Chronic fatigue that does not resolve with standard interventions.

Methylation is required for mitochondrial function, CoQ10 production, and cellular energy. When the cycle is impaired, energy production stalls at a cellular level that no amount of caffeine or adaptogens can compensate for.

Chemical and environmental sensitivity.

Methylation feeds into glutathione production and phase II liver detoxification. When these pathways are impaired, the body cannot clear normal environmental exposures efficiently. Patients become reactive to perfumes, cleaning products, new buildings, paint, and medications. They are not psychologically sensitive. They are biochemically unable to process what healthy methylation would handle without issue.

Autoimmune disease with a gut component.

Methylation status affects immune regulation and intestinal barrier integrity. Poor methylation under load often coincides with and exacerbates autoimmune activity. Addressing methylation alongside the gut and immune system produces better outcomes than treating any one in isolation.

The Gut-Methylation Connection

This is something I see frequently that most practitioners miss. The gut and methylation are deeply connected, and problems in one drive problems in the other.

Your gut is where you absorb folate, B12, B6, and the amino acids that feed the methylation cycle. If your gut is inflamed, permeable, or infected, you are not absorbing these nutrients even if your diet is excellent. I have seen patients with perfect diets and severe B12 deficiency because their gut could not absorb what they were eating. Supplementing methylfolate and B12 while the gut is malabsorbing them is like pouring water into a bucket with holes. The supplements pass through without reaching the cells that need them.

At the same time, poor methylation impairs gut barrier repair, reduces secretory IgA production, and compromises the immune system’s ability to manage the gut microbiome. Methylation is required for the production of phosphatidylcholine, a major component of the intestinal mucus layer. When methylation is impaired, the mucosal barrier thins and the gut becomes more vulnerable to damage.

The two systems pull each other down in a self-perpetuating cycle. This is why I always assess and address the gut alongside methylation. You cannot fix one without fixing the other. The gut repair sequence restores absorption so the methylation nutrients can actually reach their target. The methylation support restores the biochemical capacity the gut needs to repair itself.

Restoring Methylation Capacity

The approach is not simply “take methylfolate.” It is a sequenced protocol that addresses the whole system, because methylation does not operate in isolation.

step 1 Test the full picture.

Genetic testing for MTHFR, MTR, MTRR, CBS, and COMT. Blood panel including homocysteine, active B12, serum folate, ferritin, and vitamin D. Organic acids test for methylmalonic acid, FIGLU, pyroglutamic acid, and quinolinate. This gives you the genetics (where the vulnerabilities are) and the biochemistry (whether those vulnerabilities are currently expressing).

step 2 Address the gut.

If stool testing shows permeability, dysbiosis, or malabsorption, the gut repair sequence comes first. The nutrients you supplement will not reach their target if the gut is compromised. This step is non-negotiable and is skipped by the majority of practitioners who treat methylation.

step 3 Start methylation support gradually.

Active forms of B vitamins: methylfolate (5-MTHF), methylcobalamin (methyl B12), and pyridoxal-5-phosphate (active B6). Start at low doses and increase gradually. This is critical. Flooding a depleted system with methyl donors can cause a dramatic worsening of symptoms as the methylation cycle suddenly accelerates and mobilises toxins the body is not ready to clear.

Some patients, particularly those who are overmethylators or have slow COMT variants, react poorly to methyl donors. If anxiety, insomnia, irritability, or agitation worsen after starting methylation support, the dose is too high or the form is wrong. Hydroxocobalamin (a partially activated B12) is often better tolerated as a starting point than methylcobalamin. Folinic acid can be used as an intermediate step before methylfolate in sensitive patients.

step 4 Support the downstream pathways.

Betaine (TMG) as an alternative methyl donor that supports homocysteine recycling through a different pathway. NAC or liposomal glutathione to support the detoxification arm of the methylation pathway. Magnesium as a cofactor for hundreds of enzymatic reactions including methylation. Vitamin D, which has its own role in gene expression and immune regulation.

step 5 Address stress.

Chronic stress depletes the nutrients methylation depends on (B vitamins, magnesium, zinc) and increases the demand on the methylation cycle simultaneously. A patient can supplement perfectly and still not improve if their stress load is consuming the cofactors faster than they can be replenished. Nervous system regulation, sleep optimisation, and realistic load management are part of the methylation protocol, not additions to it.

step 6 Retest at three to six months.

Homocysteine should be trending toward below 7. Active B12 should be rising above 80 pmol/L. Organic acids markers (MMA, FIGLU, pyroglutamic acid) should be normalising. If they are not, reassess absorption (is the gut protocol adequate?), dosing (too much or too little?), and form (methylated forms vs hydroxylated forms). The data tells you whether the intervention is working. Without retesting, you are guessing.

A Clinical Example

A thirty-eight-year-old woman presented after three early pregnancy losses. She had been told everything was normal. Standard bloods showed serum B12 of 285 pmol/L (within range) and serum folate of 18 nmol/L (within range). Her GP had no explanation.

When I tested the full picture, the story was completely different. Active B12 was 42 pmol/L, severely depleted against an optimal of above 80. Homocysteine was 12.6 µmol/L, well above the optimal of below 7. Genetic testing showed homozygous MTHFR C677T (seventy per cent reduced enzyme activity), heterozygous MTR, and homozygous MTRR. Her organic acids test showed elevated methylmalonic acid (confirming cellular B12 deficiency), elevated FIGLU (confirming folate insufficiency), and elevated pyroglutamic acid (confirming glutathione depletion). Her stool test showed low beneficial bacteria, elevated calprotectin (gut inflammation), and impaired secretory IgA.

Her body had lost the capacity to run its methylation cycle under the load of three pregnancies, chronic stress, gut dysfunction, and nutrient depletion. The genes had not changed. The margin for error had disappeared.

We addressed the gut, started methylation support gradually (hydroxocobalamin first, then methylcobalamin, methylfolate, P-5-P B6, and betaine), repleted iron and vitamin D, and supported glutathione. Within six months, homocysteine normalised. She conceived naturally at month nine and carried to term. She went on to have two more healthy pregnancies.

The miscarriages were never “bad luck.” They were biology. And biology is fixable when you know where to look.